Dosing Begins in Phase 2 ReSPECT

Aug 10, 2023

Trial Name: A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

ClinicalTrials.gov Identifier: NCT01906385

Sponsor: Plus Therapeutics

Recruitment Contact: Melissa Moore, PhD, 347-570-3338, [email protected] and Norman LaFrance, MD, (CMO)215-808-0955, [email protected]

Completion Date: January 2025

Trial Name:ClinicalTrials.gov Identifier:Sponsor:Recruitment Contact:Completion Date

Previous: Global Tungsten Strip Market Research Report 2023 Next: Mines and Minerals Act: India opens doors for private cos to give lithium mining ambitions a shot in the arm

Send inquiry

Send